Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
17 avr. 2023 09h00 HE
|
ZENTALIS PHARMACEUTICALS
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy...
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
01 mars 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 ...
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
13 févr. 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 févr. 2023 17h00 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
01 févr. 2023 07h01 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2023 17h00 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
09 nov. 2022 07h00 HE
|
ZENTALIS PHARMACEUTICALS
Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from...
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
08 nov. 2022 07h01 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 nov. 2022 17h38 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...